Venture capital firm Sequoia Capital China has co-led a $25-million Series B funding round in Refuge Biotechnologies, a California-based biotech startup that leverages gene engineering technologies to develop therapeutic cells that fight cancer.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
